NASDAQ:FATE - Fate Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $11.69 +0.06 (+0.52 %) (As of 07/18/2018 04:36 AM ET)Previous Close$11.63Today's Range$11.40 - $11.8152-Week Range$2.52 - $14.45Volume224,300 shsAverage Volume669,478 shsMarket Capitalization$626.90 millionP/E Ratio-11.46Dividend YieldN/ABeta1.75 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. Receive FATE News and Ratings via Email Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:FATE CUSIPN/A Webwww.fatetherapeutics.com Phone858-875-1800 Debt Debt-to-Equity Ratio0.22 Current Ratio7.20 Quick Ratio7.20 Price-To-Earnings Trailing P/E Ratio-11.46 Forward P/E Ratio-11.13 P/E GrowthN/A Sales & Book Value Annual Sales$4.11 million Price / Sales150.35 Cash FlowN/A Price / CashN/A Book Value$1.51 per share Price / Book7.74 Profitability EPS (Most Recent Fiscal Year)($1.02) Net Income$-42,950,000.00 Net Margins-1,143.99% Return on Equity-77.27% Return on Assets-54.40% Miscellaneous Employees80 Outstanding Shares52,860,000Market Cap$626.90 Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." How were Fate Therapeutics' earnings last quarter? Fate Therapeutics Inc (NASDAQ:FATE) announced its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. The biopharmaceutical company earned $1 million during the quarter, compared to analysts' expectations of $1.82 million. Fate Therapeutics had a negative net margin of 1,143.99% and a negative return on equity of 77.27%. Fate Therapeutics's revenue was up .0% compared to the same quarter last year. View Fate Therapeutics' Earnings History. When is Fate Therapeutics' next earnings date? Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Fate Therapeutics. What price target have analysts set for FATE? 8 brokerages have issued twelve-month target prices for Fate Therapeutics' stock. Their predictions range from $7.00 to $20.00. On average, they anticipate Fate Therapeutics' stock price to reach $16.1667 in the next year. This suggests a possible upside of 38.3% from the stock's current price. View Analyst Ratings for Fate Therapeutics. What is the consensus analysts' recommendation for Fate Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Fate Therapeutics stock? Here are some recent quotes from research analysts about Fate Therapeutics stock: 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (7/17/2018) 2. HC Wainwright analysts commented, "Fate Announces Updated Data From Phase 1 of PROTECT; Reiterate Neutral Updated ProTmune data shows continued safety and efficacy. Yesterday, Fate Therapeutics announced additional Phase 1 clinical data from PROTECT. As a reminder, Fate is investigating ProTmune, a next-generation hematopoietic cell graft for the prevention of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Data reported at ASH indicated that all subjects (n=7) remained relapse-free, and there were no events of graft failure or serious adverse events (SAEs) that were deemed related to ProTmune. In the study, three out of seven subjects experienced acute GvHD in the first 100 days. However, all subjects responded to standard-of care steroid treatment, and all three cases of GvHD resolved within 5-8 days." (3/20/2018) Who are some of Fate Therapeutics' key competitors? Some companies that are related to Fate Therapeutics include Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Repligen (RGEN), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Cellectis (CLLS) and DBV Technologies (DBVT). Who are Fate Therapeutics' key executives? Fate Therapeutics' management team includes the folowing people: Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 48)Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 50)Dr. Chris M. Storgard, Chief Medical Officer (Age 52)Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 45)Dr. Stewart Abbot, Chief Devel. Officer (Age 51) Has Fate Therapeutics been receiving favorable news coverage? News coverage about FATE stock has been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fate Therapeutics earned a news sentiment score of 0.17 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Hochman Cole Investment Advisors Inc. (0.02%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics. Which major investors are selling Fate Therapeutics stock? FATE stock was sold by a variety of institutional investors in the last quarter, including Hochman Cole Investment Advisors Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics. How do I buy shares of Fate Therapeutics? Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $11.69. How big of a company is Fate Therapeutics? Fate Therapeutics has a market capitalization of $626.90 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected] MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 254 (Vote Outperform)Underperform Votes: 132 (Vote Underperform)Total Votes: 386MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?